Biogen vs. Zydus: Diroximel Fumarate Patent Dispute Settled
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Biogen Inc. et al. v. Zydus Lifesciences Limited et al. |
| Case Number | 1:23-cv-00732 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Jul 2023 – Aug 2025 2 years 1 month / 769 days |
| Outcome | Settled – Terms Confidential |
| Patents at Issue | |
| Accused Products | Diroximel Fumarate Delayed-Release Capsules, 231 mg (Generic Vumerity®) |
Case Overview
The Parties
⚖️ Plaintiffs
Biogen Inc., Biogen Swiss Manufacturing GmbH (now Biogen International GmbH), and Alkermes Pharma Ireland Limited. Global neuroscience biopharmaceutical leader and specialty pharmaceutical company with IP interests in Vumerity®.
🛡️ Defendants
Cadila Healthcare, Ltd. (Zydus Lifesciences), Zydus Pharmaceuticals (USA) Inc., and Zydus Worldwide DMCC. A major generic pharmaceutical conglomerate with a significant U.S. ANDA pipeline.
The Patents at Issue
This litigation involved three U.S. patents forming a layered IP fortress protecting the diroximel fumarate MS therapy:
- • U.S. Patent No. 8,669,281 — Directed to fumarate ester compounds and pharmaceutical compositions.
- • U.S. Patent No. 10,080,733 — Covering formulation and dosing aspects of diroximel fumarate.
- • U.S. Patent No. 9,090,558 — Relating to pharmaceutical compositions and methods of treatment.
Developing a generic equivalent?
Check if your formulation or dosing might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case concluded via **stipulated dismissal without prejudice**, pursuant to a confidential settlement agreement. No damages were publicly awarded, and no injunctive relief was granted or denied by the court. The Delaware District Court retains jurisdiction to enforce the Agreement and resolve future disputes.
Key Legal Issues
This was a classic Hatch-Waxman infringement action, initiated by Zydus’s ANDA filing. The legal battleground centered on whether Zydus’s proposed generic formulation would infringe the three asserted patents, and whether any of those patents were subject to validity challenges.
Because the case settled without judicial rulings, no claim construction orders, validity determinations, or infringement findings entered the public record — limiting the precedential impact but not the strategic significance.
Filing a new drug patent or ANDA?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the pharmaceutical space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in the MS drug space
- See which companies are most active in diroximel fumarate IP
- Understand claim construction patterns for fumarate esters
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Fumarate ester compounds & formulations
3 Asserted Patents
Covering composition, formulation, method
Strategic Settlement
Common outcome in Hatch-Waxman
✅ Key Takeaways
For Patent Attorneys & Litigators
Multi-patent ANDA strategies covering composition, formulation, and method claims create substantial settlement leverage.
Search related case law →Delaware District Court remains the premier venue for Hatch-Waxman patent disputes due to its specialized judiciary.
Explore precedents →For IP Professionals & R&D Teams
Iterative formulation development can generate durable IP protection, extending commercial exclusivity.
Start FTO analysis for my product →Comprehensive FTO analysis for generics must account for clustered patent families with staggered expiry dates.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.